Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2151 to 2200 of 3761 results for treatment

  1. Diabetes: suspended from retinal screening (IND70)

    This indicator covers the proportion of eligible people with diabetes who are suspended from diabetic eye screening due to previous screening results. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG89

  2. Hypertension: haematuria for target organ damage (IND122)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a test for haematuria in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM76

  3. Laparoscopic liver resection (HTG83)

    Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.

  4. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.

  5. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

  6. Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache (HTG378)

    Evidence-based recommendations on implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache. This involves implanting a device into the cheek to stimulate a group of nerves called the sphenopalatine ganglion.

  7. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  8. Joint distraction for ankle osteoarthritis (HTG393)

    Evidence-based recommendations on joint distraction for ankle osteoarthritis in adults. This involves fixing a metal frame around the ankle and pulling the joint slightly apart using the frame to allow cartilage regrowth.

  9. Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse (HTG445)

    Evidence-based recommendations on uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse in women. This involves attaching mesh from the uterus or cervix either to the bone at the base of the spine or to a ligament in the pelvis to hold the uterus in place.

  10. Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation (HTG180)

    Evidence-based recommendations on thoracoscopic epicardial radiofrequency ablation for atrial fibrillation. This involves using heat to destroy the selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.

  11. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  12. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  13. Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia (HTG187)

    Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia. This involves using heat to destroy selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.

  14. Psychological treatments: What is the cost effectiveness of providing tailored psychological treatments for people with epilepsy?

    Question Psychological treatments: What is the cost effectiveness of providing tailored psychological treatments for...

  15. Hypothyroidism: register (IND138)

    This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.

  16. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

  17. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  18. Laparoscopic deroofing of simple renal cysts (HTG145)

    Evidence-based recommendations on laparoscopic deroofing of simple renal cysts. This involves draining the cyst and removing part of the cyst wall through small cuts in the abdomen (keyhole surgery).

  19. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  20. Hypertension: lifestyle advice (IND146)

    This indicator covers the percentage of patients diagnosed with hypertension (diagnosed on or after 1 April 2009) who are given lifestyle advice in the preceding 12 months for: smoking cessation, safe alcohol consumption and healthy diet. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM112

  21. Diabetes: lipid-lowering therapies for primary prevention of CVD (T2DM and 10% risk) (IND274)

    This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  22. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  23. Cerebral palsy in adults (QS191)

    This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.

  24. NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

    collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on...

  25. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

  26. Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)

    This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.

  27. Diabetes: annual albumin creatinine test (IND111)

    This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  28. Diabetes: gestational diabetes annual HbA1c test (IND173)

    This indicator covers the percentage of women who have had gestational diabetes, diagnosed more than 12 months ago, who have had an HbA1c test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM151

  29. Lipid disorders: FH assessment and diagnosis (new readings) (IND261)

    This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245

  30. Atrial fibrillation: DOACs and Vitamin K antagonists (IND247)

    This indicator covers the percentage of patients with atrial fibrillation and a last recorded CHA2DS2-VASc score of 2 or more who are currently prescribed a direct-acting oral anticoagulant (DOAC) if eligible, or a vitamin K antagonist if not eligible for a DOAC or a DOAC is declined, clinically unsuitable or not indicated. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM231

  31. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

  32. Radiofrequency ablation of the soft palate for snoring (HTG327)

    Evidence-based recommendations on radiofrequency ablation of the soft palate for snoring. This involves using an electrode device to puncture and send radiofrequency energy into the soft palate to scar and tighten it.

  33. Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea (HTG672)

    Evidence-based recommendations on daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea. This involves placing a mouthpiece around the tongue inside the mouth (intraoral). It delivers electrical stimulation to the muscles of the tongue (neuromuscular). The aim is to reduce airway obstruction during sleep.

  34. Cyanoacrylate glue occlusion for varicose veins (HTG540)

    Evidence-based recommendations on cyanoacrylate glue occlusion for varicose veins. This involves injecting medical glue (cyanoacrylate) into a vein to close it with the aim of improving symptoms.

  35. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (HTG549)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.

  36. YAG laser vitreolysis for symptomatic vitreous floaters (HTG644)

    Evidence-based recommendations on YAG laser vitreolysis for symptomatic vitreous floaters. This involves a special type of laser (YAG) firing short pulses of energy into the floaters, to break them up (vitreolysis) and reduce sight disturbances.

  37. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (HTG501)

    Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.

  38. Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina (HTG464)

    Evidence-based recommendations on laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina. This involves inserting mesh to hold the uterus or the top of the vagina in place.

  39. Pregnancy and neonates: hip screening (IND77)

    This indicator covers the proportion of babies with a screen positive newborn hip result who attend for ultrasound scan of the hips within the designated timescale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG96

  40. Myocardial infarction: medication for MI more than 12 months ago (IND126)

    This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80

  41. Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124

  42. Smoking: smoking status of people with long-term conditions (IND156)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126

  43. Multiple long-term conditions: asking about falls (IND208)

    This indicator covers the percentage of patients (aged 65 years and over) with moderate or severe frailty who have been asked whether they have had a fall, about the total number of falls and about the type of falls, in the last 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM187

  44. Diabetes: IFCC-HbA1c 75mmol/mol or less (IND136)

    This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.

  45. Screening: cervical (25 to 64 years) (IND321)

    This indicator covers the percentage of women eligible for cervical screening and aged 25 to 64 years at end of the period reported whose notes record that an adequate cervical screening test has been performed in the previous 5.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  46. Endovascular closure of patent ductus arteriosus (HTG59)

    Evidence-based recommendations on endovascular closure of patent ductus arteriosus. This involves placing a blocking device into the heart, which stays in place permanently and the body’s tissue grows around it.

  47. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  48. Laparoscopic cryotherapy for renal cancer (HTG271)

    Evidence-based recommendations on laparoscopic cryotherapy for renal cancer. This involves inserting a surgical instrument (cryoprobe) to apply freezing temperatures to the tumour and destroy the cancer cells.

  49. clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)

    NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .

  50. The OPTIMIZER smart system for managing heart failure (MIB186)

    NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .